ADVERTISEMENT
Safety and Efficacy of Vaccination With Folate Receptor Alpha for Ovarian Cancer
04/01/2021
Roisin O'Cearbhaill, MD, Memorial Sloan Kettering Cancer Center, New York, discusses a phase 2 trial evaluating the safety and efficacy of TPIV200 versus GM-CSF alone in patients with high-grade, platinum-sensitive ovarian cancer, the data of which were presented at the virtual 2020 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement